We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA, INDUSTRY MULL PHARMACOGENOMIC COMBINATION PRODUCTS
FDA, INDUSTRY MULL PHARMACOGENOMIC COMBINATION PRODUCTS
July 30, 2004
As the FDA prepares to issue a final guidance document on submitting pharmacogenomic data, the agency is in the early stages of developing a new guidance on how a genetic testing device could be co-developed with a drug or biologic to create a new combination product.